Back to search

Article

SARS-CoV-2 antibody seroprevalence in cancer patients on systemic antineoplastic treatment in the first wave of the COVID-19 pandemic in Portugal

2022-02-02

Abstract excerpt

At the time of the first wave of the COVID-19 pandemic cancer patients were considered to be at high risk of serious illness and had a higher exposure risk since they needed frequent and non- deferrable hospital visits. Serologic tests were not routinely used and seroprevalence in this population was unknown. A single-center cross-sectional study was developed to determine the seroprevalence of anti- SARS-CoV-2 an...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d147dedb-ed32-5111-9672-a9b45cdef882
DOI
10.1101/2022.01.31.22270178
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
SARS-CoV-2 antibody seroprevalence in cancer patients on systemic antineoplastic treatment in the first wave of the COVID-19 pandemic in PortugalDOI 10.1101/2022.01.31.22270178
Scottish COVID Cancer Immunity Prevalence (SCCAMP) - a Longitudinal Study of Patients with Cancer Receiving Active Anti-Cancer Treatment During the COVID-19 PandemicSemantic proximity
Scottish COVID CAncer iMmunity Prevalence (SCCAMP) - a longitudinal study of patients with cancer receiving active anti-cancer treatment during the COVID-19 pandemicSemantic proximity
Incidence and Immunomic Features of Apyretic COVID-19 in Patients Affected by Solid Tumors: a Prospective Cohort Study.Semantic proximity
Seroprevalence study prior and post vaccination in Cancer patients in Principality of Andorra (COVONCO study)Semantic proximity
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studySemantic proximity
Antibody Responses to SARS-CoV-2 Infection in Cancer PatientsSemantic proximity
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity
Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity
First results from the UK COVID-19 Serology in Oncology Staff Study (CSOS)Semantic proximity
Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity
SARS-CoV-2 Positive Hospitalized Cancer Patients during the Italian Outbreak: The Cohort Study in Reggio EmiliaSemantic proximity
Breakthrough SARS-CoV-2 Infections Among Patients with Cancer Following Two and Three Doses of COVID-19 mRNA VaccinesSemantic proximity
Select a neighboring publication to make it the new centre.